BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32520003)

  • 1. [Oncology PET radiopharmaceuticals in clinic and research in 2020].
    Mikecz P; Fekete A; Tóth G; Környei J; Bali T; Cservenyák T; Borbély K
    Magy Onkol; 2020 Jun; 64(2):104-111. PubMed ID: 32520003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PET radiopharmaceuticals: novelties and new possibilities].
    Környei J; Mikecz P; Tóth G
    Magy Onkol; 2014 Dec; 58(4):245-50. PubMed ID: 25517442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings.
    Follacchio GA; De Feo MS; De Vincentis G; Monteleone F; Liberatore M
    Curr Radiopharm; 2018; 11(1):22-33. PubMed ID: 29231149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET Radiopharmaceuticals for Personalized Medicine.
    Sharma S
    Curr Drug Targets; 2016; 17(16):1894-1907. PubMed ID: 27440185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current trends in using PET radiopharmaceuticals for diagnostics in oncology].
    Adam J; Kadeřávek J; Kužel F; Vašina J; Rehák Z
    Klin Onkol; 2014; 27 Suppl 1():S129-36. PubMed ID: 24945550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET tracers based on (86)Y.
    Huang J; Cui L; Wang F; Liu Z
    Curr Radiopharm; 2011 Apr; 4(2):122-30. PubMed ID: 22191651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods for the Production of Radiolabeled Bioagents for ImmunoPET.
    Arroyo A; Lyashchenko SK; Lewis JS
    Methods Mol Biol; 2024; 2729():117-142. PubMed ID: 38006494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.
    Bauman A; Valverde IE; Fischer CA; Vomstein S; Mindt TL
    J Nucl Med; 2015 Oct; 56(10):1569-74. PubMed ID: 26251418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.
    Zeglis BM; Lewis JS
    J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
    Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
    Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.
    Ikotun OF; Lapi SE
    Future Med Chem; 2011 Apr; 3(5):599-621. PubMed ID: 21526898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in copper radiopharmaceuticals.
    Hao G; Singh AN; Oz OK; Sun X
    Curr Radiopharm; 2011 Apr; 4(2):109-21. PubMed ID: 22191650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond 18F-FDG: Characterization of PET/CT and PET/MR Scanners for a Comprehensive Set of Positron Emitters of Growing Application--18F, 11C, 89Zr, 124I, 68Ga, and 90Y.
    Soderlund AT; Chaal J; Tjio G; Totman JJ; Conti M; Townsend DW
    J Nucl Med; 2015 Aug; 56(8):1285-91. PubMed ID: 26135111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production and Use of the First-Row Transition Metal PET Radionuclides
    Chaple IF; Lapi SE
    J Nucl Med; 2018 Nov; 59(11):1655-1659. PubMed ID: 30262514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
    Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unconventional nuclides for radiopharmaceuticals.
    Holland JP; Williamson MJ; Lewis JS
    Mol Imaging; 2010 Feb; 9(1):1-20. PubMed ID: 20128994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 44Sc-DOTA-BN[2-14]NH2 in comparison to 68Ga-DOTA-BN[2-14]NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?
    Koumarianou E; Loktionova NS; Fellner M; Roesch F; Thews O; Pawlak D; Archimandritis SC; Mikolajczak R
    Appl Radiat Isot; 2012 Dec; 70(12):2669-76. PubMed ID: 23037921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.